Loading…
4CPS-068 Effectiveness of dolutegravir and lamivudine therapy in a two drug regimen in a third level hospital
Background and importanceSimplification of antiretroviral treatments (ART) improves adherence and comfort, and may prevent some adverse effects caused by ART.Aim and objectivesTo assess the effectiveness (plasma viral load (PVL test)
Saved in:
| Published in: | European journal of hospital pharmacy. Science and practice 2020-03, Vol.27 (Suppl 1), p.A79-A79 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | A79 |
| container_issue | Suppl 1 |
| container_start_page | A79 |
| container_title | European journal of hospital pharmacy. Science and practice |
| container_volume | 27 |
| creator | Fernández Zamora, C Rodríguez Martínez, T Meroño Saura, MA Clavijos Bautista, S Plaza Aniorte, J Pacheco López, P Sánchez, MÁ Carvajal Ibáñez Caturla, J Nájera Pérez, MD |
| description | Background and importanceSimplification of antiretroviral treatments (ART) improves adherence and comfort, and may prevent some adverse effects caused by ART.Aim and objectivesTo assess the effectiveness (plasma viral load (PVL test) |
| doi_str_mv | 10.1136/ejhpharm-2020-eahpconf.169 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_bmj_p</sourceid><recordid>TN_cdi_proquest_journals_2382406410</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2382406410</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1269-70295c7b7a2b58b1a81023853efe082201aaf6593c422d35c201754402ce8c573</originalsourceid><addsrcrecordid>eNo9kEtLw0AUhQdRsGj_w6Dr1Hkns5RSH1BQUNfDJLlppiSZOHlId278o_4SU9q6OpfDuefAh9ANJQtKubqDbdmWNtQRI4xEYMs2802xoEqfoRkjIo60VuL8_5bqEs27zqVEcp5owfUMebF8fYuISn6_f1ZFAVnvRmig67AvcO6roYdNsKML2DY5rmztxiF3DeC-hGDbHXYNtrj_8jgPwwYH2LgamqNbujD9wAgVLn3Xut5W1-iisFUH86NeoY-H1fvyKVq_PD4v79dRSpnSUUyYllmcxpalMkmpTShhPJEcCiAJY4RaWyipeSYYy7nMJieWQhCWQZLJmF-h20NvG_znAF1vtn4IzTRpph4miBKUTCl5SKX11rTB1TbsDCVmj9ec8Jo9XnPCaya8_A8NanMl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2382406410</pqid></control><display><type>article</type><title>4CPS-068 Effectiveness of dolutegravir and lamivudine therapy in a two drug regimen in a third level hospital</title><source>PubMed Central</source><creator>Fernández Zamora, C ; Rodríguez Martínez, T ; Meroño Saura, MA ; Clavijos Bautista, S ; Plaza Aniorte, J ; Pacheco López, P ; Sánchez, MÁ Carvajal ; Ibáñez Caturla, J ; Nájera Pérez, MD</creator><creatorcontrib>Fernández Zamora, C ; Rodríguez Martínez, T ; Meroño Saura, MA ; Clavijos Bautista, S ; Plaza Aniorte, J ; Pacheco López, P ; Sánchez, MÁ Carvajal ; Ibáñez Caturla, J ; Nájera Pérez, MD</creatorcontrib><description>Background and importanceSimplification of antiretroviral treatments (ART) improves adherence and comfort, and may prevent some adverse effects caused by ART.Aim and objectivesTo assess the effectiveness (plasma viral load (PVL test) <50 copies/mL) of the combination of dolutegravir (DTG) and lamivudine (3TC) without a third antiretroviral drug in patients diagnosed with HIV infection who were previously treated with a three drug regimen of ART.Material and methodsIn January 2019, we studied a cohort of patients who were undergoing treatment with DTG+3TC in a two drug regimen. Once these patients were selected, we carried out a prospective study of the PVL test after 6 months of treatment.ResultsThirty-three patients were receiving treatment with the DTG+3TC combination in January 2019. Patients were aged 24–72 years (mean 46.27 years). The previous PVL test was undetectable in 69.70% of patients, detectable (<50 copies/mL) in 27.27% of patients and 1 patient (3.03%) had a viral load of >50 copies/mL. After 6 months of treatment, the PVL test was undetectable in 75.75% of patients, detectable (<50 copies/mL) in 15.15% and detectable (>50 copies/mL) in 3.03%. Two patients discontinued treatment.Conclusion and relevanceThe combination of DTG+3TC seemed to be an effective alternative to other ART when we re-evaluated patients after 6 months of treatment. We found a PVL <50 copies/mL in 96.96% and 90.90% of patients before and after the change in ART.References and/or acknowledgements1. Cahn P, Madero JS, Arribas JR, et al. GEMINI Study Team. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet 2019;393:143–155.No conflict of interest.</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2020-eahpconf.169</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Antiretroviral drugs ; HIV ; Human immunodeficiency virus</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2020-03, Vol.27 (Suppl 1), p.A79-A79</ispartof><rights>Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Fernández Zamora, C</creatorcontrib><creatorcontrib>Rodríguez Martínez, T</creatorcontrib><creatorcontrib>Meroño Saura, MA</creatorcontrib><creatorcontrib>Clavijos Bautista, S</creatorcontrib><creatorcontrib>Plaza Aniorte, J</creatorcontrib><creatorcontrib>Pacheco López, P</creatorcontrib><creatorcontrib>Sánchez, MÁ Carvajal</creatorcontrib><creatorcontrib>Ibáñez Caturla, J</creatorcontrib><creatorcontrib>Nájera Pérez, MD</creatorcontrib><title>4CPS-068 Effectiveness of dolutegravir and lamivudine therapy in a two drug regimen in a third level hospital</title><title>European journal of hospital pharmacy. Science and practice</title><description>Background and importanceSimplification of antiretroviral treatments (ART) improves adherence and comfort, and may prevent some adverse effects caused by ART.Aim and objectivesTo assess the effectiveness (plasma viral load (PVL test) <50 copies/mL) of the combination of dolutegravir (DTG) and lamivudine (3TC) without a third antiretroviral drug in patients diagnosed with HIV infection who were previously treated with a three drug regimen of ART.Material and methodsIn January 2019, we studied a cohort of patients who were undergoing treatment with DTG+3TC in a two drug regimen. Once these patients were selected, we carried out a prospective study of the PVL test after 6 months of treatment.ResultsThirty-three patients were receiving treatment with the DTG+3TC combination in January 2019. Patients were aged 24–72 years (mean 46.27 years). The previous PVL test was undetectable in 69.70% of patients, detectable (<50 copies/mL) in 27.27% of patients and 1 patient (3.03%) had a viral load of >50 copies/mL. After 6 months of treatment, the PVL test was undetectable in 75.75% of patients, detectable (<50 copies/mL) in 15.15% and detectable (>50 copies/mL) in 3.03%. Two patients discontinued treatment.Conclusion and relevanceThe combination of DTG+3TC seemed to be an effective alternative to other ART when we re-evaluated patients after 6 months of treatment. We found a PVL <50 copies/mL in 96.96% and 90.90% of patients before and after the change in ART.References and/or acknowledgements1. Cahn P, Madero JS, Arribas JR, et al. GEMINI Study Team. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet 2019;393:143–155.No conflict of interest.</description><subject>Antiretroviral drugs</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNo9kEtLw0AUhQdRsGj_w6Dr1Hkns5RSH1BQUNfDJLlppiSZOHlId278o_4SU9q6OpfDuefAh9ANJQtKubqDbdmWNtQRI4xEYMs2802xoEqfoRkjIo60VuL8_5bqEs27zqVEcp5owfUMebF8fYuISn6_f1ZFAVnvRmig67AvcO6roYdNsKML2DY5rmztxiF3DeC-hGDbHXYNtrj_8jgPwwYH2LgamqNbujD9wAgVLn3Xut5W1-iisFUH86NeoY-H1fvyKVq_PD4v79dRSpnSUUyYllmcxpalMkmpTShhPJEcCiAJY4RaWyipeSYYy7nMJieWQhCWQZLJmF-h20NvG_znAF1vtn4IzTRpph4miBKUTCl5SKX11rTB1TbsDCVmj9ec8Jo9XnPCaya8_A8NanMl</recordid><startdate>202003</startdate><enddate>202003</enddate><creator>Fernández Zamora, C</creator><creator>Rodríguez Martínez, T</creator><creator>Meroño Saura, MA</creator><creator>Clavijos Bautista, S</creator><creator>Plaza Aniorte, J</creator><creator>Pacheco López, P</creator><creator>Sánchez, MÁ Carvajal</creator><creator>Ibáñez Caturla, J</creator><creator>Nájera Pérez, MD</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>202003</creationdate><title>4CPS-068 Effectiveness of dolutegravir and lamivudine therapy in a two drug regimen in a third level hospital</title><author>Fernández Zamora, C ; Rodríguez Martínez, T ; Meroño Saura, MA ; Clavijos Bautista, S ; Plaza Aniorte, J ; Pacheco López, P ; Sánchez, MÁ Carvajal ; Ibáñez Caturla, J ; Nájera Pérez, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1269-70295c7b7a2b58b1a81023853efe082201aaf6593c422d35c201754402ce8c573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antiretroviral drugs</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fernández Zamora, C</creatorcontrib><creatorcontrib>Rodríguez Martínez, T</creatorcontrib><creatorcontrib>Meroño Saura, MA</creatorcontrib><creatorcontrib>Clavijos Bautista, S</creatorcontrib><creatorcontrib>Plaza Aniorte, J</creatorcontrib><creatorcontrib>Pacheco López, P</creatorcontrib><creatorcontrib>Sánchez, MÁ Carvajal</creatorcontrib><creatorcontrib>Ibáñez Caturla, J</creatorcontrib><creatorcontrib>Nájera Pérez, MD</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Databases</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fernández Zamora, C</au><au>Rodríguez Martínez, T</au><au>Meroño Saura, MA</au><au>Clavijos Bautista, S</au><au>Plaza Aniorte, J</au><au>Pacheco López, P</au><au>Sánchez, MÁ Carvajal</au><au>Ibáñez Caturla, J</au><au>Nájera Pérez, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>4CPS-068 Effectiveness of dolutegravir and lamivudine therapy in a two drug regimen in a third level hospital</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><date>2020-03</date><risdate>2020</risdate><volume>27</volume><issue>Suppl 1</issue><spage>A79</spage><epage>A79</epage><pages>A79-A79</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>Background and importanceSimplification of antiretroviral treatments (ART) improves adherence and comfort, and may prevent some adverse effects caused by ART.Aim and objectivesTo assess the effectiveness (plasma viral load (PVL test) <50 copies/mL) of the combination of dolutegravir (DTG) and lamivudine (3TC) without a third antiretroviral drug in patients diagnosed with HIV infection who were previously treated with a three drug regimen of ART.Material and methodsIn January 2019, we studied a cohort of patients who were undergoing treatment with DTG+3TC in a two drug regimen. Once these patients were selected, we carried out a prospective study of the PVL test after 6 months of treatment.ResultsThirty-three patients were receiving treatment with the DTG+3TC combination in January 2019. Patients were aged 24–72 years (mean 46.27 years). The previous PVL test was undetectable in 69.70% of patients, detectable (<50 copies/mL) in 27.27% of patients and 1 patient (3.03%) had a viral load of >50 copies/mL. After 6 months of treatment, the PVL test was undetectable in 75.75% of patients, detectable (<50 copies/mL) in 15.15% and detectable (>50 copies/mL) in 3.03%. Two patients discontinued treatment.Conclusion and relevanceThe combination of DTG+3TC seemed to be an effective alternative to other ART when we re-evaluated patients after 6 months of treatment. We found a PVL <50 copies/mL in 96.96% and 90.90% of patients before and after the change in ART.References and/or acknowledgements1. Cahn P, Madero JS, Arribas JR, et al. GEMINI Study Team. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet 2019;393:143–155.No conflict of interest.</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/ejhpharm-2020-eahpconf.169</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2047-9956 |
| ispartof | European journal of hospital pharmacy. Science and practice, 2020-03, Vol.27 (Suppl 1), p.A79-A79 |
| issn | 2047-9956 2047-9964 |
| language | eng |
| recordid | cdi_proquest_journals_2382406410 |
| source | PubMed Central |
| subjects | Antiretroviral drugs HIV Human immunodeficiency virus |
| title | 4CPS-068 Effectiveness of dolutegravir and lamivudine therapy in a two drug regimen in a third level hospital |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T22%3A49%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=4CPS-068%E2%80%85Effectiveness%20of%20dolutegravir%20and%20lamivudine%20therapy%20in%20a%20two%20drug%20regimen%20in%20a%20third%20level%20hospital&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Fern%C3%A1ndez%20Zamora,%20C&rft.date=2020-03&rft.volume=27&rft.issue=Suppl%201&rft.spage=A79&rft.epage=A79&rft.pages=A79-A79&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2020-eahpconf.169&rft_dat=%3Cproquest_bmj_p%3E2382406410%3C/proquest_bmj_p%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b1269-70295c7b7a2b58b1a81023853efe082201aaf6593c422d35c201754402ce8c573%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2382406410&rft_id=info:pmid/&rfr_iscdi=true |